Pomegranate Compound PGG Breaks Down Heart and Nerve Disease Protein Deposits

Most existing treatments for transthyretin amyloidosis work upstream: they either stabilize the transthyretin protein so it does not misfold, or they suppress its production. Both approaches have clinical value, but neither addresses the amyloid fibrils that have already formed and accumulated in cardiac and nerve tissue. For patients diagnosed after significant deposits have built up, this gap in the treatment landscape is a real problem.

A study published in iScience from Kumamoto University in Japan takes a different angle. Rather than preventing TTR misfolding, the researchers sought compounds that could dismantle pre-formed amyloid directly - what they call an "amyloid disruptor" strategy.

Screening 1,509 plant extracts

TTR amyloidosis occurs when transthyretin, a protein that normally transports thyroid hormones and vitamin A through the bloodstream, misfolds and aggregates into insoluble fibrils. These accumulate primarily in the heart and peripheral nerves, causing progressive organ damage. The condition is linked to both inherited mutations and a wild-type form more common in older adults.

To find candidates capable of attacking existing deposits, the team screened 1,509 plant extracts from a natural product library. Extracts from pomegranate leaves and branches - Punica granatum - stood out for their ability to disrupt pre-formed TTR fibrils. Further chemical analysis narrowed the active component to a single molecule: 1,2,3,4,6-penta-O-galloyl-beta-D-glucose, abbreviated as PGG.

PGG is a polyphenol containing five galloyl groups attached to a glucose core. The structural analysis revealed that this arrangement of multiple galloyl units is essential for activity - compounds with fewer of these groups showed weaker effects. This specificity hints at a defined mechanism of interaction with the fibril surface, though the full molecular picture requires further work.

Selectivity for TTR over Alzheimer's amyloid

In laboratory experiments, PGG effectively disassembled amyloid fibrils formed by both mutant and wild-type TTR. A notable finding was selectivity: under the same test conditions, PGG left amyloid-beta fibrils - the deposits associated with Alzheimer's disease - largely intact. This suggests that PGG does not simply dissolve any amyloid it encounters but interacts with TTR fibrils through some degree of molecular specificity. That distinction matters for therapeutic development, where off-target effects on other amyloid systems could create problems.

Animal model results

The team moved from cell-free experiments to a living organism: Caenorhabditis elegans, the small nematode worm used as a model organism across genetics and aging research. The researchers used worms engineered to express human TTR fragments, which then deposit in the animals' tissues. Treatment with PGG reduced protein deposits in these worms and, perhaps more strikingly, extended both lifespan and healthspan - a measure of time spent in good functional condition rather than simply alive.

Nematode studies are a standard early step in compound screening but carry obvious limitations as predictors of human biology. The worm nervous system, immune response, and drug metabolism differ substantially from mammalian systems, and results that hold in C. elegans frequently do not translate to higher organisms.

Human tissue test

A more directly relevant test involved amyloid fibrils extracted from cardiac tissue of a patient with hereditary TTR amyloidosis. PGG successfully disrupted these patient-derived fibrils, not just the laboratory-produced versions. This step is meaningful because patient-derived fibrils can differ structurally from fibrils assembled in vitro and may be more resistant to disruption.

The finding adds a layer of clinical relevance to the early-stage data, though it represents a single patient sample and cannot be generalized without confirmation across a broader range of TTR variants and disease stages.

Scope of the remaining work

PGG is a naturally occurring compound found in several plant species, including pomegranates and certain oak galls where it has been studied for its antioxidant properties. Its bioavailability, stability in the human bloodstream, ability to reach target tissues, and safety profile at therapeutic doses remain essentially unknown. Polyphenols as a class are often poorly absorbed and rapidly metabolized, which can limit their effectiveness even when they show strong activity in cell-based or simple organism studies.

Whether PGG would need to be chemically modified to function as a drug, how it would be dosed, and whether it interacts safely with existing TTR therapies are all questions that standard preclinical and clinical development pipelines would need to address before any human trials could proceed.

The broader category of amyloid-disrupting compounds represents an active area of pharmaceutical research not just for TTR amyloidosis but for conditions including Alzheimer's disease, Parkinson's disease, and systemic amyloidosis. If PGG's mechanism can be confirmed and refined, it could serve as a scaffold for designing more potent and bioavailable analogs.